Welcome to Seeking Alpha's Wall Street Breakfast, where we cover the top news for investors every morning.

Good morning. Today is Tuesday, November 19th. I'm Julie Morgan.

Fate Therapeutics releases promising data on its lupus treatment.

Super microcomputer has a plan, and Blackstone is reportedly set to acquire a sandwich

chain. Fate therapeutics closed 12% higher on Monday after soaring as much as 73%. The increase was on the

news that the first patient in the company's phase one, autoimmunity study for its CAR-T-cell therapy candidate,

FT-819, is in remission for lupus six months after treatment. The company said the patient,

an African-American Asian woman, diagnosed with lupus nephritis, received fludarabine-free conditioning,

followed by a single dose of FT-819.

The woman achieved clinical remission as of the six-month follow-up,

free of all immunosuppressive therapies, as of the data cutoff date of November 11th.

The company said it is also enrolling a second treatment arm under the Phase 1 autoimmunity study to evaluate a single

dose of Ft819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with a

different form of lupus. The new arm is being conducted in parallel with the study's conditioning arm.

Data from the Phase 1 studies was presented at the American College of Rheumatology

convergence meeting in Washington, D.C.

In a note Monday, BFA said it was upgrading its rating of the stock to neutral from underperform,

but keeping its price target at three bucks.

BFA said that while it viewed the update

as supporting the company's pivot from oncology to immunology, it would like to see additional

data for more patients before making changes to its model. BFA noted that fate has guided that it

will present additional data from the first three-dose patients at the American

...